Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
15
×
boston blog main
boston top stories
clinical trials
15
×
life sciences
national blog main
national top stories
15
×
biotech
fda
new york blog main
san francisco blog main
san francisco top stories
new york top stories
deals
investing
rna interference
san diego blog main
startups
alnylam pharmaceuticals
drugs
hepatitis b
hereditary transthyretin amyloidosis
patisiran
roche
san diego top stories
third rock ventures
akcea therapeutics
alexion pharmaceuticals
atlas venture
blackstone group
boehringer ingelheim
david goldstein
depression
eli lilly
epilepsy
essential tremor
eventide asset management
gene therapy
indiana blog main
indiana top stories
What
medicines
drug
ago
fda
new
therapeutics
biotechs
company
drugs
genetic
ipo
ipos
medicine
million
research
aiming
alnylam
approved
data
dicerna
digital
disease
diseases
disorder
emerged
gets
long
muscle
patients
pharma
pharmaceuticals
praxis
precision
raised
raises
rna
rnai
roche
specifically
stop
Language
unset
Current search:
boston
×
" national top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
Renovia Raises $42M to Back Digital Treatment for Incontinence
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision